Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 26;217(8):e20190673. doi: 10.1084/jem.20190673

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Lin et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — CD40 activation repairs cDC1 maturation in KPC tumors. (A) Timeline of subcutaneous implantation of KPC cell line 6419.c5, administration of CD40 agonist (FGK45), and harvest of tissues for flow cytometric analysis. (B) Enumeration of cDC1s per live cells in subcutaneous KPC tumors from untreated and FGK45-treated mice. (C) Enumeration of CD11c^intMHCII^hi migratory/activated cDC1s in the TdLN. (D) Expression of Ccr7 in CD11c⁺ cells purified from the iLNs of healthy mice and TdLNs of untreated and FGK45-treated mice bearing subcutaneously implanted KPC tumors. (E) Expression of maturation markers CD40, CD80, CD86, MHC II (I-A/I-E), and PD-L1 on cDC1s from the tumors of untreated and FGK45-treated mice. MFI, mean fluorescence intensity. (F and G) Maturation marker expression on cDC1s from the (F) TdLN and (G) spleen of healthy mice, untreated tumor-bearing mice, and FGK45-treated tumor-bearing mice. (H) Enumeration of H-2Kb:SIINFEKL tetramer–positive splenic CD8⁺ T cells from healthy mice, untreated tumor-bearing KPC mice, and FGK45-treated tumor-bearing KPC mice 12 d following subcutaneous implantation of OVA-expressing clonal KPC cell line 4662.V6ova. 100 µg FGK45 was administered on day 9 after implantation. Error bars indicate mean ± SD. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05 (two-tailed Student’s t test in B, C, E; one-way ANOVA with Tukey’s HSD post-test in D, F, G, H). Data shown are representative of four independent experiments with at least three mice per group.